Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
PDL BioPharma, Inc. |
---|---|
Information provided by: | PDL BioPharma, Inc. |
ClinicalTrials.gov Identifier: | NCT00032305 |
The purpose of the study is to evaluate an intravenous (by injection) investigational medication to treat severe ulcerative colitis refractory to steroid therapy. The research is being conducted at up to 8 clinical research sites in the US and is open to both men and women ages 18 to 70 years old. Participants in the study will have a number of visits to a research site. All study-related care and medication is provided to qualified participants at no cost: this includes all visits, examinations and laboratory work.
Condition | Intervention | Phase |
---|---|---|
Ulcerative Colitis |
Drug: Visilizumab |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Dose Comparison, Single Group Assignment, Safety Study |
Official Title: | A Phase I, Dose-Escalation, Pilot Study of Visilizumab in Patients With Severe Ulcerative Colitis That is Refractory to Corticosteroids |
Estimated Enrollment: | 20 |
Study Start Date: | March 2002 |
A Phase I, dose-escalation, pilot study designed to obtain safety and tolerability data on visilizumab administered to patients with severe ulcerative colitis that has failed to respond to steroid therapy. Patients who are currently receiving IV corticosteroids, but whose disease has not responded after at least 5 days of this therapy, will be eligible for the study.
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
United States, California | |
Cedars-Sinai Medical Center | |
Los Angeles, California, United States | |
University of California | |
San Francisco, California, United States, 94115 | |
United States, Georgia | |
Atlanta Gastroenterology Associates | |
Atlanta, Georgia, United States | |
United States, Illinois | |
The University of Chicago Medical Center | |
Chicago, Illinois, United States | |
United States, Minnesota | |
Mayo Clinic | |
Rochester, Minnesota, United States, 55905 | |
United States, New York | |
Mount Sinai School of Medicine | |
New York, New York, United States | |
United States, Pennsylvania | |
University of Pittsburgh School of Medicine | |
Pittsburgh, Pennsylvania, United States |
Study ID Numbers: | 291-406 |
Study First Received: | March 14, 2002 |
Last Updated: | August 1, 2008 |
ClinicalTrials.gov Identifier: | NCT00032305 |
Health Authority: | United States: Food and Drug Administration |
Colitis Gastrointestinal Disease Digestive System Disease Intestinal Disease Colonic Disease |
Digestive System Diseases Gastrointestinal Diseases Ulcer Colonic Diseases Inflammatory Bowel Diseases |
Colitis, Ulcerative Gastroenteritis Intestinal Diseases Colitis |
Pathologic Processes |